Has the French Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the French Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 20.1x. The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 2.0x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	€107.9b	€54.6b	€5.3b	18.7x	20.4x	2x
Fri, 15 May 2026	€105.9b	€54.6b	€5.3b	18.2x	20x	1.9x
Sun, 12 Apr 2026	€115.4b	€54.0b	€5.4b	20x	21.4x	2.1x
Tue, 10 Mar 2026	€108.6b	€54.0b	€5.4b	21.7x	20.2x	2x
Thu, 05 Feb 2026	€114.8b	€53.8b	€5.5b	22.2x	21x	2.1x
Sat, 03 Jan 2026	€114.4b	€53.0b	€7.0b	21.3x	16.4x	2.2x
Mon, 01 Dec 2025	€119.3b	€53.0b	€7.0b	22.8x	17.1x	2.2x
Wed, 29 Oct 2025	€120.7b	€53.0b	€7.0b	21.9x	17.3x	2.3x
Fri, 26 Sep 2025	€107.8b	€52.8b	€6.9b	19.6x	15.6x	2x
Sun, 24 Aug 2025	€120.6b	€52.8b	€6.9b	19.7x	17.4x	2.3x
Tue, 22 Jul 2025	€114.6b	€52.1b	€6.7b	20.2x	17.2x	2.2x
Thu, 19 Jun 2025	€113.5b	€52.1b	€6.7b	18.4x	17x	2.2x
Sat, 17 May 2025	€124.5b	€52.1b	€6.7b	18x	18.7x	2.4x
Mon, 14 Apr 2025	€121.5b	€51.2b	€5.9b	17.2x	20.4x	2.4x
Wed, 12 Mar 2025	€147.7b	€51.1b	€5.9b	18.2x	24.9x	2.9x
Fri, 07 Feb 2025	€143.7b	€51.1b	€6.3b	18.7x	22.9x	2.8x
Sun, 05 Jan 2025	€130.0b	€55.2b	€5.1b	19x	25.5x	2.4x
Tue, 03 Dec 2024	€128.5b	€55.2b	€5.1b	19.4x	25.2x	2.3x
Thu, 31 Oct 2024	€137.8b	€55.2b	€5.1b	20.6x	27x	2.5x
Sat, 28 Sep 2024	€143.5b	€53.8b	€4.8b	23.3x	29.9x	2.7x
Mon, 26 Aug 2024	€139.5b	€53.8b	€4.8b	20.1x	29.1x	2.6x
Wed, 24 Jul 2024	€130.3b	€52.9b	€5.2b	21.2x	25.2x	2.5x
Fri, 21 Jun 2024	€124.8b	€52.9b	€5.2b	20.7x	24.1x	2.4x
Sun, 19 May 2024	€126.5b	€52.9b	€5.2b	21.6x	24.5x	2.4x
Tue, 16 Apr 2024	€123.2b	€52.7b	€6.0b	20.2x	20.4x	2.3x
Thu, 14 Mar 2024	€124.4b	€52.6b	€6.0b	20.5x	20.6x	2.4x
Sat, 10 Feb 2024	€122.6b	€53.0b	€6.3b	19.5x	19.6x	2.3x
Mon, 08 Jan 2024	€131.5b	€52.2b	€9.7b	18.4x	13.5x	2.5x
Wed, 06 Dec 2023	€121.5b	€52.2b	€9.7b	17.3x	12.5x	2.3x
Fri, 03 Nov 2023	€123.0b	€52.2b	€9.7b	15.9x	12.7x	2.4x
Sun, 01 Oct 2023	€142.6b	€52.6b	€9.3b	18.6x	15.4x	2.7x
Tue, 29 Aug 2023	€139.7b	€52.6b	€9.3b	21.2x	15.1x	2.7x
Thu, 27 Jul 2023	€135.2b	€52.6b	€9.1b	19.6x	14.8x	2.6x
Sat, 24 Jun 2023	€137.2b	€52.6b	€9.1b	15.4x	15x	2.6x


FR Market	2.70%
Healthcare	-0.55%
Pharma	-1.77%
Pharma	-1.77%

	Company	Last Price	7D	1Y	Valuation
	ALTHX THX Pharma Société Anonyme	€3.94	24.5% +€10.7m	373.6%	PS67.4x
	MEDCL MedinCell	€28.02	0.8% +€7.9m	86.2%	PS31x

Announcement • Jun 15

Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes

Sanofi received accelerated approval from the US Food and Drug Administration (FDA) for Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions. The approval was supported by data from the PROTECT phase 3 study (clinical study identifier: NCT03875729), evaluating beta cell function as assessed by significantly slowing the decrease in mean C-peptide levels (area under the curve after a four-hour, mixed-meal tolerance test; difference in least-squares means 0.13 pmol/mL; 95% confidence interval: 0.09-0.17; p<0.001) at trial completion, compared to placebo, as well as data from the broader clinical development program that included over 900 patients who received Tzield. Adverse events observed in the PROTECT phase 3 study were consistent with previous studies. The most common adverse reactions were lymphopenia, vomiting, rash, leukopenia, diarrhea, neutropenia, increased liver transaminase, and headache. Serious events such as cytokine release syndrome and life-threatening cases of viral reactivation have been reported with Tzield. Patients who are immunocompromised are at increased risk for viral reactivation. This indication is granted under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory study(ies). Medicines that receive accelerated approval are intended to treat serious conditions that fill an unmet medical need, based on a surrogate endpoint reasonably likely to predict clinical benefit. The confirmatory BETA-PRESERVE phase 3 study (clinical study identifier: NCT07088068) was initiated and is currently enrolling participants. Prior to this approval in recently diagnosed stage 3 T1D, in April 2026, the FDA expanded the indication to delay the onset of stage 3 T1D in adults and children eight years and older with stage 2 T1D, to include children aged one year and above. It is also approved to delay the onset of stage 3 T1D in adults and children eight years and older with stage 2 T1D in the UK, the EU (under the name Teizeild), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. Regulatory reviews are ongoing in other jurisdictions around the world. Tzield was previously designated by the FDA as breakthrough therapy and was granted orphan drug designation, for investigational medicines that treat rare diseases affecting fewer than 200,000 people in the US. PROTECT was a phase 3, randomized, double blind, placebo-controlled, multinational study. It enrolled 328 children and adolescents (Tzield n=217, placebo n=111) aged eight to 17 years diagnosed with clinical stage 3 T1D in the preceding six weeks; randomization ratio of Tzield to placebo was 2:1. Participants received a first course of 12 daily infusions (of either Tzield or placebo) at randomization, followed by a second course of 12 daily infusions after 26 weeks (approximately six months). All participants received standard-of-care medicines as required. T1D is a progressive autoimmune disease where the body’s ability to regulate blood sugar levels is impacted due to the gradual destruction of insulin producing beta cells by one’s own immune system. There are four stages to the progression of T1D: In stage 1, the autoimmune attack to the beta cells has started, and this can be detected by the presence of 2 or more T1D-related autoantibodies in the blood. During stage 1, blood sugar levels are in a normal range (normoglycemia). At this stage, T1D is presymptomatic. In stage 2 (also presymptomatic), in addition to the presence of 2 or more T1D-related autoantibodies, blood sugar levels are now abnormal (dysglycemia) due to the progressive loss of beta cells /beta-cell function. Stage 3 (also known as clinical stage) comes once a significant portion of the beta cells have been destroyed. At this point, rising blood sugar levels reach the point of clinical hyperglycemia (which defines diabetes), and many people will start to experience the classic symptoms that come with the onset of stage 3 T1D: increased thirst, frequent urination, unexplained weight loss, blurred vision, and generalized fatigue. Management of stage 3 T1D requires daily and burdensome insulin replacement therapy. Stage 4 is defined as long-standing autoimmune T1D, often accompanied by evidence of chronic diabetic complications, where little to no beta-cell function remains (it’s been estimated that beta-cell mass is reduced by up to 95%). At this point, the T1D-related autoantibodies might not be present anymore in the blood, as most beta cells have been rendered useless by the autoimmune attack. Tzield (teplizumab) is a CD3-directed monoclonal antibody. Tzield is the first disease-modifying therapy in autoimmune T1D; it was approved in the US in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. In April 2026, the FDA expanded this indication to include children aged one year and above. It is also approved in to delay the onset of stage 3 T1D in adults and children eight years and older with stage 2 in the UK, the EU (under the name Teizeild), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. Other regulatory reviews are ongoing.

French (CAC) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

MedinCell Stock Eyes Growth as UZEDY Royalties Rise and Olanzapine LAI Nears US Launch

IPN: Oncology And Rare Liver Pipeline Progress Will Shape Balanced Future Outlook

Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes

VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing

EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings

Upcoming dividend of €1.35 per share

New minor risk - Shareholder dilution

Advicenne S.A. Announces Board Changes

Dividend increased to €0.93

THX Pharma Société Anonyme, Annual General Meeting, Jun 23, 2026